Last reviewed · How we verify
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| 15-Valent Pneumococcal Conjugate Vaccine | 15-Valent Pneumococcal Conjugate Vaccine | marketed | ||||
| Meningococcal ACYW135 Polysaccharide Conjugate Vaccine | Meningococcal ACYW135 Polysaccharide Conjugate Vaccine | phase 3 | Polysaccharide conjugate vaccine | Meningococcal serogroup A, C, Y, and W-135 polysaccharide capsules | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Jiangsu Province Centers for Disease Control and Prevention · 1 shared drug class
- Sanofi Pasteur, a Sanofi Company · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd:
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd pipeline updates — RSS
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd pipeline updates — Atom
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-zhifei-lvzhu-biopharmaceutical-co-ltd. Accessed 2026-05-17.